243 related articles for article (PubMed ID: 26846851)
1. Phenotype-based Discovery of 2-[(E)-2-(Quinolin-2-yl)vinyl]phenol as a Novel Regulator of Ocular Angiogenesis.
Reynolds AL; Alvarez Y; Sasore T; Waghorne N; Butler CT; Kilty C; Smith AJ; McVicar C; Wong VH; Galvin O; Merrigan S; Osman J; Grebnev G; Sjölander A; Stitt AW; Kennedy BN
J Biol Chem; 2016 Apr; 291(14):7242-55. PubMed ID: 26846851
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Development of the Quininib Series of Ocular Drugs.
Mahon N; Slater K; O'Brien J; Alvarez Y; Reynolds A; Kennedy B
J Ocul Pharmacol Ther; 2022; 38(1):33-42. PubMed ID: 35089801
[TBL] [Abstract][Full Text] [Related]
3. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.
Butler CT; Reynolds AL; Tosetto M; Dillon ET; Guiry PJ; Cagney G; O'Sullivan J; Kennedy BN
J Biol Chem; 2017 Mar; 292(9):3552-3567. PubMed ID: 28035003
[TBL] [Abstract][Full Text] [Related]
4. A sustained release formulation of novel quininib-hyaluronan microneedles inhibits angiogenesis and retinal vascular permeability in vivo.
Galvin O; Srivastava A; Carroll O; Kulkarni R; Dykes S; Vickers S; Dickinson K; Reynolds AL; Kilty C; Redmond G; Jones R; Cheetham S; Pandit A; Kennedy BN
J Control Release; 2016 Jul; 233():198-207. PubMed ID: 27086168
[TBL] [Abstract][Full Text] [Related]
5. Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer.
Murphy AG; Casey R; Maguire A; Tosetto M; Butler CT; Conroy E; Reynolds AL; Sheahan K; O'Donoghue D; Gallagher WM; Fennelly D; Kennedy BN; O'Sullivan J
Sci Rep; 2016 Oct; 6():34523. PubMed ID: 27739445
[TBL] [Abstract][Full Text] [Related]
6. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats.
Santulli RJ; Kinney WA; Ghosh S; Decorte BL; Liu L; Tuman RW; Zhou Z; Huebert N; Bursell SE; Clermont AC; Grant MB; Shaw LC; Mousa SA; Galemmo RA; Johnson DL; Maryanoff BE; Damiano BP
J Pharmacol Exp Ther; 2008 Mar; 324(3):894-901. PubMed ID: 18083913
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide, an anti-tumor drug, regulates retinal endothelial cell function: Implication for treating ocular neovascular disorder.
Dong LF; Yao J; Wang XQ; Shan K; Yang H; Yan B; Jiang Q
Biochem Biophys Res Commun; 2015 Oct; 465(4):678-84. PubMed ID: 26255966
[TBL] [Abstract][Full Text] [Related]
8. Vitamin D receptor agonists regulate ocular developmental angiogenesis and modulate expression of dre-miR-21 and VEGF.
Merrigan SL; Kennedy BN
Br J Pharmacol; 2017 Aug; 174(16):2636-2651. PubMed ID: 28547797
[TBL] [Abstract][Full Text] [Related]
9. Novel targets against retinal angiogenesis in diabetic retinopathy.
Wang S; Park JK; Duh EJ
Curr Diab Rep; 2012 Aug; 12(4):355-63. PubMed ID: 22638940
[TBL] [Abstract][Full Text] [Related]
10. Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis.
Gong Y; Shao Z; Fu Z; Edin ML; Sun Y; Liegl RG; Wang Z; Liu CH; Burnim SB; Meng SS; Lih FB; SanGiovanni JP; Zeldin DC; Hellström A; Smith LEH
EBioMedicine; 2016 Nov; 13():201-211. PubMed ID: 27720395
[TBL] [Abstract][Full Text] [Related]
11. microRNA-181a inhibits ocular neovascularization by interfering with vascular endothelial growth factor expression.
Yang C; Tahiri H; Cai C; Gu M; Gagnon C; Hardy P
Cardiovasc Ther; 2018 Jun; 36(3):e12329. PubMed ID: 29608244
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy.
Cao R; Jensen LD; Söll I; Hauptmann G; Cao Y
PLoS One; 2008 Jul; 3(7):e2748. PubMed ID: 18648503
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis.
Nakao S; Arima M; Ishikawa K; Kohno R; Kawahara S; Miyazaki M; Yoshida S; Enaida H; Hafezi-Moghadam A; Kono T; Ishibashi T
Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):4323-8. PubMed ID: 22661475
[TBL] [Abstract][Full Text] [Related]
14. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
Andreoli CM; Miller JW
Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
[TBL] [Abstract][Full Text] [Related]
15. RhoB antibody alters retinal vascularization in models of murine retinopathy.
Almonte-Baldonado R; Bravo-Nuevo A; Gerald D; Benjamin LE; Prendergast GC; Laury-Kleintop LD
J Cell Biochem; 2019 Jun; 120(6):9381-9391. PubMed ID: 30536763
[TBL] [Abstract][Full Text] [Related]
16. Mammalian Target of Rapamycin (mTOR) as a Potential Therapeutic Target in Pathological Ocular Angiogenesis.
Nakahara T; Morita A; Yagasaki R; Mori A; Sakamoto K
Biol Pharm Bull; 2017; 40(12):2045-2049. PubMed ID: 29199229
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of APE1/Ref-1 for Neovascular Eye Diseases: From Biology to Therapy.
Hartman GD; Lambert-Cheatham NA; Kelley MR; Corson TW
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638620
[TBL] [Abstract][Full Text] [Related]
18. An arylidene-thiazolidinedione derivative, GPU-4, without PPARγ activation, reduces retinal neovascularization.
Nakamura S; Hayashi K; Takizawa H; Murase T; Tsuruma K; Shimazawa M; Kakuta H; Nagasawa H; Hara H
Curr Neurovasc Res; 2011 Feb; 8(1):25-34. PubMed ID: 21208163
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage.
Silva RLE; Kanan Y; Mirando AC; Kim J; Shmueli RB; Lorenc VE; Fortmann SD; Sciamanna J; Pandey NB; Green JJ; Popel AS; Campochiaro PA
Sci Transl Med; 2017 Jan; 9(373):. PubMed ID: 28100839
[TBL] [Abstract][Full Text] [Related]
20. Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation.
Seo S; Kim MK; Kim RI; Yeo Y; Kim KL; Suh W
Exp Mol Med; 2020 Oct; 52(10):1744-1753. PubMed ID: 33051573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
